Omid Farokhzad

Omid Farokhzad

Associate Professor

Brigham and Women’s Hospital, Harvard Medical School

Omid Farokhzad is an Associate Professor at Harvard Medical School (HMS) and a physicianscientist in the Department of Anesthesiology at Brigham and Women’s Hospital (BWH). He completed his post-graduate clinical and post-doctoral research trainings, respectively, at the BWH/HMS and MIT in the laboratory of Institute Professor Robert Langer. He received his M.D. and M.A. from Boston University School of Medicine. Dr. Farokhzad directs the Laboratory of Nanomedicine and Biomaterials at BWH, which he established in 2004. He is a faculty member of the Brigham Research Institute Cancer Research Center at BWH. He is additionally a member of the Dana Farber/Harvard Cancer Center Programs in Prostate Cancer and Cancer Cell Biology. He is a Research Affiliate in the Harvard-MIT Division of Health Sciences and Technology (HST). Dr. Farokhzad has extensive experience with the development of therapeutic nanoparticle technologies; most notably, he pioneered the high throughput combinatorial development and screening of multifunctional nanoparticles for medical applications. Dr. Farokhzad has authored approximately 95 papers and holds more then 125 issued/pending US and International patents. The technologies that Dr. Farokhzad has developed with collaborators at HMS, DFCI, Cornell and MIT have formed the basis for: 1) a new class of targeted nanoparticles for treatment of important human diseases including cancer and cardiovascular disease; 2) a new class of synthetic nanoparticle vaccines for prophylactic and therapeutic applications now in a Phase I clinical trial for smoking cessation and relapse prevention; and 3) a new class of integrative combination nanomedicines for synergistic treatment of cancers, inflammation/pain, and infectious diseases. These technologies formed the foundational platform for the launch of three biotechnology companies: BIND Therapeutics, Selecta Biosciences, Blend Therapeutics, which are translating the aforementioned academic innovations toward commercialization and societal impact. The targeted nanoparticles for the treatment of cancers (named BIND-014), entered Phase I human clinical trials in January 2011, marking the first-in-human testing of a targeted polymeric nanoparticle for cancer chemotherapy. Initial results as published in SCIENCE Translational Medicine demonstrated that in patients with advanced solid tumors, BIND-014 displays remarkable pharmacological properties and cases of effective tumor shrinkage. The Phase II clinical trials for the treatment of lung, bladder and prostate cancers have been initiated. In November 2011, a nicotine nanoparticle vaccine (named SEL-068), entered clinical trials for smoking cessation and relapse prevention, and the clinical translation of SEL-068 marked the first-in-human testing of a targeted polymeric nanoparticle vaccine. Dr. Farokhzad has delivered more than 110 invited talks including 85 at national and international conferences; several of which were keynote addresses. He has served as an ad hoc reviewer for over 30 international peer-reviewed journals including serving on the editorial board or advisory board of six journals including Nanomedicine, Theranostics, Drug Delivery, and ChemPlusChem. Dr. Farokhzad was elected to the College of the Fellows of the American Institute of Medical and biological Engineering. He was among the Nano50 winners by NASA Nanotech Briefs, which awards the most innovative people and design ideas that will revolutionize nanotechnology, and was among the 15 recipients across all industries to receive the All Star Distinguished Achievement Award from the Mass High Tech Journal for his contributions to the Life Sciences industry. He was an Ernst & Young Entrepreneur of the Year awardee for the Northeast Region. The Boston Globe selected him among the top innovators in Massachusetts.

Sponsor & Exhibitor Opportunities

 Exhibit and Showcase
 Become a Sponsor

Please contact: Denise Lee


TechConnect Acceleration Partners:

BASF
BayerMaterialScience
Battelle
Bosch
bp
DOW
GE
Honda
Hyundai
Ingersoll Rand
intel
Lockheed Martin
MWV
Merck
novaris
Panasonic
Procter And Gamble
PPG
Roche
Sanofi
Shell_GameChanger
siemens
solvay
Toyota.gif

In Partnership with

NSTI


Sponsorship Opportunities: Contact Denise Lee

Free Subscription

E-mail:

pbh(); ?>